Karin Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Karin Hu has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Ana Filipa David
Division of Nephrology and Dialysis, Department of Internal Medicine III, Medical University of Vienna, 1090 Vienna, Austria
2 shared publications - Andreas Heinzel
Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria
2 shared publications - Rainer Oberbauer
Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria
2 shared publications - Roman Reindl-Schwaighofer
Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria
2 shared publications - Thomas Wekerle
Division of Transplantation, Department of General Surgery, Medical University of Vienna, 1090 Vienna, Austria
2 shared publications - Andreas Salat
Department of General Surgery, Division of Transplantation, Medical University of Vienna, Vienna, Austria
1 shared publication
Latest Publications
- 17 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (854) , eaee6850
Donor bone marrow together with recipient regulatory T cells induces chimerism without irradiation in kidney transplantation
Cotransplantation of donor bone marrow (BM) has yielded a therapeutic benefit in clinical trials of kidney transplantation by inducing chimerism-based tolerance, but this was dependent on unfavorable recipient irradiation. Additional regulatory T (T reg ) cell administration can overcome the need for myelosuppression, but this has been demonstrated only in mice so far. Here, we conducted a controlled, phase 1/2a trial of combined BM and T reg cell therapy in HLA-mismatched living-donor kidney transplantation (NCT03867617). Six patients received polyclonal recipient T reg cells and donor BM cells (BMCs) immediately posttransplant. Immunosuppression consisted of thymoglobulin, belatacept, sirolimus, steroids, and short-course tocilizumab. The control group received no T reg cells, BMCs, or tocilizumab. Total leukocyte donor chimerism was detected across all patients in the study group posttransplantation. This was not observed in any patient belonging to the control group, consequently meeting the primary end point of higher chimerism levels in the study versus control groups ( P = 0.001). Chimerism was observed across multiple lineages, with up to 4% in T cells. For three patients in the study group, immunosuppression could be minimized to belatacept monotherapy. Antidonor reactivity was decreased in in vitro T cell proliferation assays, suggesting specific downmodulation of the antidonor T cell response. In addition, expansion of antidonor T cell clones was shown by T cell receptor sequencing analysis to be dampened in the study versus control groups. This trial serves as a proof of concept for a combination cell therapy that induces chimerism-based immunomodulation in kidney transplantation without the need for irradiation.
- 17 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (854) , eaee6850
Donor bone marrow together with recipient regulatory T cells induces chimerism without irradiation in kidney transplantation
Cotransplantation of donor bone marrow (BM) has yielded a therapeutic benefit in clinical trials of kidney transplantation by inducing chimerism-based tolerance, but this was dependent on unfavorable recipient irradiation. Additional regulatory T (T reg ) cell administration can overcome the need for myelosuppression, but this has been demonstrated only in mice so far. Here, we conducted a controlled, phase 1/2a trial of combined BM and T reg cell therapy in HLA-mismatched living-donor kidney transplantation (NCT03867617). Six patients received polyclonal recipient T reg cells and donor BM cells (BMCs) immediately posttransplant. Immunosuppression consisted of thymoglobulin, belatacept, sirolimus, steroids, and short-course tocilizumab. The control group received no T reg cells, BMCs, or tocilizumab. Total leukocyte donor chimerism was detected across all patients in the study group posttransplantation. This was not observed in any patient belonging to the control group, consequently meeting the primary end point of higher chimerism levels in the study versus control groups ( P = 0.001). Chimerism was observed across multiple lineages, with up to 4% in T cells. For three patients in the study group, immunosuppression could be minimized to belatacept monotherapy. Antidonor reactivity was decreased in in vitro T cell proliferation assays, suggesting specific downmodulation of the antidonor T cell response. In addition, expansion of antidonor T cell clones was shown by T cell receptor sequencing analysis to be dampened in the study versus control groups. This trial serves as a proof of concept for a combination cell therapy that induces chimerism-based immunomodulation in kidney transplantation without the need for irradiation.
- Open Access
- 13 March 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (8) , 1833-1844
Donor-reactive clonotypes are overrepresented in the urinary T cell repertoire during kidney transplant rejection and show distinct dynamics in the circulation
- 13 March 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (8) , 1833-1844
Open AccessDonor-reactive clonotypes are overrepresented in the urinary T cell repertoire during kidney transplant rejection and show distinct dynamics in the circulation